ANAB
USDAnaptysBio Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$35.970
Kõrge
$36.500
Madal
$34.595
Maht
0.76M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
971.8M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.52M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec.
Anaptys Announces Participation in November Investor Conferences
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president
Stifel Maintains Buy on AnaptysBio, Raises Price Target to $80
Stifel analyst Alex Thompson maintains AnaptysBio with a Buy and raises the price target from $55 to $80.
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
New data reinforce rosnilimab's efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.